Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Cassava Sciences, Inc. (SAVA)

35.83   1.69 (4.95%) 12-02 16:00
Open: 34 Pre. Close: 34.14
High: 36.47 Low: 33.7301
Volume: 1,150,879 Market Cap: 1,495(M)

Technical analysis

as of: 2022-12-02 4:25:58 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 45.12     One year: 51.71
Support: Support1: 29.5    Support2: 24.54
Resistance: Resistance1: 38.63    Resistance2: 44.27
Pivot: 35.25
Moving Average: MA(5): 34.62     MA(20): 35.13
MA(100): 31.13     MA(250): 32.95
MACD: MACD(12,26): -0.4     Signal(9): -0.4
Stochastic oscillator: %K(14,3): 36.7     %D(3): 34.4
RSI: RSI(14): 52.3
52-week: High: 62.49  Low: 13.84
Average Vol(K): 3-Month: 2,410 (K)  10-Days: 1,151 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ SAVA ] has closed below upper band by 44.0%. Bollinger Bands are 12.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 36.5 - 36.67 36.67 - 36.83
Low: 33.31 - 33.5 33.5 - 33.68
Close: 35.51 - 35.82 35.82 - 36.11

Company Description

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Headline News

Tue, 29 Nov 2022
Cassava Sciences (NASDAQ:SAVA) Price Target Cut to $11.00 by Analysts at Univest Sec - MarketBeat

Mon, 28 Nov 2022
Noteworthy Monday Option Activity: QCOM, SAVA, MBI - Nasdaq

Wed, 23 Nov 2022
Sava Licence Exploration Results - AccessWire

Tue, 22 Nov 2022
Sava Re’s net profit drops 19% as inflation, high claims provisions bite - Business Insurance

Mon, 21 Nov 2022
Cassava (SAVA) Stock: Risk/Reward Equation Is More Balanced, Says Analyst - Nasdaq

Sun, 20 Nov 2022
Sava Juzbasic - The Times of Northwest Indiana

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 40 (M)
Shares Float 38 (M)
% Held by Insiders 5.6 (%)
% Held by Institutions 26.6 (%)
Shares Short 9,370 (K)
Shares Short P.Month 10,780 (K)

Stock Financials

EPS -1.16
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.96
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -19.1
Return on Equity (ttm) -30.6
Qtrly Rev. Growth 0
Gross Profit (p.s.) -0.62
Sales Per Share 0
EBITDA (p.s.) -1.81
Qtrly Earnings Growth 0
Operating Cash Flow -64 (M)
Levered Free Cash Flow -42 (M)

Stock Valuations

PE Ratio -30.89
PEG Ratio -0.3
Price to Book value 7.22
Price to Sales 0
Price to Cash Flow -22.38

Stock Dividends

Dividend 5.25
Forward Dividend 0
Dividend Yield 14.6%
Dividend Pay Date 2017-05-09
Ex-Dividend Date 2012-12-12
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.